MedTrace Logo

Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration

NCT04746963 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2024-03-22

Study results available
· View outcomes & findings →

Summary

This is an open-label, dose-escalating, 48-week study assessing the safety, tolerability, bioactivity and duration of action of a single intravitreal injection of 0.1 mg, 0.25 mg, or 0.5 mg AXT107 in approximately 18 subjects (up to 6 subjects per dose) with nAMD.

Conditions

  • Neovascular Age-Related Macular Degeneration (nAMD)

Interventions

DRUG

AXT107 0.1 mg

Single intravitreal injection of AXT107 0.1 mg/eye (low dose)

DRUG

AXT107 0.25 mg

Single intravitreal injection of AXT107 0.25 mg/eye (mid dose)

DRUG

AXT107 0.5 mg

Single intravitreal injection of AXT107 0.5 mg/eye (high dose)

Sponsors & Collaborators

  • AsclepiX Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Amir Shojaei, PhD · Asclepix Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2022-10-01
Completion
2022-10-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04746963 on ClinicalTrials.gov